


Stabilis



Vincristine sulfate



Noms commerciaux

Cellecristin	Allemagne
Citomid	Chili, Colombie, Mexique, Pérou
Crisovin	Colombie, Equateur, Mexique
Cytocristin	Malaisie
DBL vincristine sulfate	Malaisie, Nouvelle Zélande
Farmistin	Allemagne
Marqibo	Etats Unis d'Amérique
Nefixol	Mexique
Oncocristin	Colombie
Oncovin	Arabie Saoudite, Autriche, Colombie, Danemark, Emirats Arabes Unis, Finlande, France, Grande Bretagne, Luxembourg, Maroc, Mexique, Suède, Suisse
Onkocristin	Allemagne
Sindovin	Iran
Sulfato de vincristine	Vénézuela
Unicristin	Pérou
Vinblax	Mexique
Vincasar	Etats Unis d'Amérique, Mexique
Vincrisin	Belgique
Vincristin	Allemagne, Autriche, Hongrie, Suisse
Vincristina	Argentine, Chili, Colombie, Equateur, Espagne, Iran, Islande, Italie, Pérou, Vénézuela
Vincristine	France, Grèce, Luxembourg, Malaisie, Maroc, Norvège, Suède, Suisse, Tunisie, Turquie
Vincristine sulfat	Turquie
Vincristine sulfate	Canada, Etats Unis d'Amérique
Vincristine sulphate	Egypte, Emirats Arabes Unis, Grande Bretagne, Irlande, Malaisie, Nouvelle Zélande, Pologne
Vincristinesulfaat	Pays bas
Vincristinum	Luxembourg
Vincrisul	Espagne
Vinlon Lyo	Pérou
Vinracine	Egypte, Malaisie
Vintec	Mexique



Stabilité des solutions

		1 mg/ml	4°C		21			481
PVC		0,02 mg/ml	4°C		7			144
PVC		0,01 >> 0,12 mg/ml	4°C		7			1602
PE		0,001 & 0,02 mg/ml	25°C		7			1520
PP		0,02 mg/ml	25°C		21			481
PP		0,02 mg/ml	4°C		21			481
PP		0,033 >> 0,121 mg/ml	25°C		7			3119
PP		0,033 >> 0,121 mg/ml	4°C		7			3119
PP	RL	0,02 mg/ml	25°C		21			481
PP	RL	0,02 mg/ml	4°C		21			481
POF		0,05 mg/ml	2-8°C		84			3214
POF		0,05 mg/ml	25°C		84			3214
		0,025 mg/ml	2-8°C		84			3214
		0,025 mg/ml	25°C		84			3214
		0,025 >> 0,15 mg/ml	4°C		7			1602
		0,1 mg/ml	2-8°C		84			3214
		0,1 mg/ml	25°C		84			3214



Stabilité en mélange

		0,005 mg/ml	20°C-23°C		Granisetron hydrochloride : 0,5 mg/ml	4	
PVC		0,2 mg/ml	37°C		Doxorubicin hydrochloride : 2 mg/ml	7	
PVC		0,2 mg/ml	8°C		Doxorubicin hydrochloride : 2 mg/ml	14	
PVC		0,028 mg/ml	30°C		Ondansetron hydrochloride : 0,96 mg/ml Doxorubicin hydrochloride : 0,8 mg/ml	5	
PVC		0,036 mg/ml	35°C		Doxorubicin hydrochloride : 1,67 mg/ml	4	
PVC		0,036 mg/ml	4°C		Doxorubicin hydrochloride : 1,67 mg/ml	7	
POF		0,005 mg/ml	2-6°C		Doxorubicin hydrochloride : 0,12 mg/ml Etoposide phosphate : 0,6 mg/ml	5	
POF		0,010 mg/ml	2-6°C		Doxorubicin hydrochloride : 0,24 mg/ml Etoposide phosphate : 1,2 mg/ml	5	

POF		0,016 mg/ml	2-6°C		Doxorubicin hydrochloride : 0,4 mg/ml Etoposide phosphate : 2 mg/ml	5		1606
POF		0,002 mg/ml	23°C-25°C		Doxorubicin hydrochloride : 0,050 mg/ml Etoposide : 0,250 mg/ml	72		1033
POF		0,001 mg/ml	23°C-25°C		Doxorubicin hydrochloride : 0,025 mg/ml Etoposide : 0,125 mg/ml	96		1033
POF		0,0014 mg/ml	23°C-25°C		Doxorubicin hydrochloride : 0,035 mg/ml Etoposide : 0,175 mg/ml	96		1033
POF		0,033 & 0,053 mg/ml	25°C		Doxorubicin hydrochloride : 1,4 mg/ml	4		2094
POF		0,0016 mg/ml	31°C-33°C		Doxorubicin hydrochloride : 0,040 mg/ml Etoposide : 0,200 mg/ml	72		1033
POF		0,005 mg/ml	35°C-40°C		Doxorubicin hydrochloride : 0,12 mg/ml Etoposide phosphate : 0,6 mg/ml	5		1606
POF		0,010 mg/ml	35°C-40°C		Doxorubicin hydrochloride : 0,24 mg/ml Etoposide phosphate : 1,2 mg/ml	5		1606
POF		0,016 mg/ml	35°C-40°C		Doxorubicin hydrochloride : 0,4 mg/ml Etoposide phosphate : 2 mg/ml	5		1606
POF		0,033 & 0,053 mg/ml	8°C		Doxorubicin hydrochloride : 1,4 mg/ml	14		2094
PSX		0,033 mg/ml	25°C		Doxorubicin hydrochloride : 1,4 mg/ml	14		408
PSX		0,033 mg/ml	37°C		Doxorubicin hydrochloride : 1,4 mg/ml	7		408
PSX		0,033 mg/ml	25°C		Doxorubicin hydrochloride : 1,4 mg/ml	14		408
PSX		0,033 mg/ml	37°C		Doxorubicin hydrochloride : 1,4 mg/ml	7		408
PI		0,005 mg/ml	2-6°C		Doxorubicin hydrochloride : 0,12 mg/ml Etoposide phosphate : 0,6 mg/ml	14		4102
PI		0,01 mg/ml	2-6°C		Doxorubicin hydrochloride : 0,24 mg/ml Etoposide phosphate : 1,2 mg/ml	14		4102
PI		0,016 mg/ml	2-6°C		Doxorubicin hydrochloride : 0,4 mg/ml Etoposide phosphate : 2 mg/ml	14		4102
PI		0,005 mg/ml	35°C		Doxorubicin hydrochloride : 0,12 mg/ml Etoposide phosphate : 0,6 mg/ml	7		4102
PI		0,01 mg/ml	35°C		Doxorubicin hydrochloride : 0,24 mg/ml Etoposide phosphate : 1,2 mg/ml	7		4102
PI		0,016 mg/ml	35°C		Doxorubicin hydrochloride : 0,4 mg/ml Etoposide phosphate : 2 mg/ml	7		4102
?		0,5 mg/ml	20°C-23°C		Topotecan : 0,028 mg/ml	4		1026


















































Facteur influençant la stabilité

				703
				857
	Nylon			167
	NaHCO ₃			150



Compatibilités

			
	Vincristine sulfate : 0.05 mg/ml Allopurinol sodium : 3 mg/ml		307
	Vincristine sulfate : 0.05 mg/ml Amifostine : 10 mg/ml		3
	Vincristine sulfate : 0.05 mg/ml Amphotericin B cholesteryl sulfate complex : 0.83 mg/ml		921
	Vincristine sulfate : 0.05 mg/ml Anidulafungin : 0.5 mg/ml		1982
	Vincristine sulfate : 0.05 mg/ml Aztreonam : 40 mg/ml		99
			3644
	Vincristine sulfate : 0,05 mg/ml Caspofungin acetate : 0,7 mg/ml		2247
			3578
	Vincristine sulfate : 0.05 mg/ml Cladribine : 0.5 mg/ml		1496
	Vincristine sulfate : 0.05 mg/ml Cladribine : 0.015 mg/ml		1496
	Vincristine sulfate : 0.004 mg/ml Cytarabine : 0.016 mg/ml		431
	Vincristine sulfate : 0,036 mg/ml Doxorubicin hydrochloride : 1,67 mg/ml		32
	Vincristine sulfate : 0,033 mg/ml Doxorubicin hydrochloride : 1,4 mg/ml		408
	Vincristine sulfate : 0,033 mg/ml Doxorubicin hydrochloride : 1,4 mg/ml		408
	Vincristine sulfate : 1 mg/ml Doxorubicin hydrochloride : 2 mg/ml		763
	Vincristine sulfate : 0.05 mg/ml Doxorubicin hydrochloride liposome peg : 0.4 mg/ml		251
	Vincristine sulfate : 1 mg/ml Droperidol : 2,5 mg/ml		763
	Vincristine sulfate : 0.05 mg/ml Etoposide phosphate : 5 mg/ml		1410
	Vincristine sulfate : 0.05 mg/ml Filgrastim : 30 µg/ml		244
	Vincristine sulfate : 1 mg/ml Fludarabine phosphate : 1 mg/ml		492
	Vincristine sulfate : 1 mg/ml Fluorouracil : 50 mg/ml		763
	Vincristine sulfate : 0.004 mg/ml Fluorouracil : 0.010 mg/ml		431
	Vincristine sulfate : 1 mg/ml Folate calcium : 10 mg/ml		763
			763

		Vincristine sulfate : 0.05 mg/ml Gemcitabine hydrochloride : 10 mg/ml		1423
		Vincristine sulfate : 0.01 & 0.34 mg/ml Granisetron hydrochloride : 1 mg/ml		57
		Vincristine sulfate : 1 mg/ml Heparin sodium : 1000 UI/ml		763
		Vincristine sulfate : 1 mg/ml Idarubicin hydrochloride : 1 mg/ml		491
		Vincristine sulfate : 0.05 mg/ml Lansoprazole : 0.55 mg/ml		1625
		Vincristine sulfate : 0.05 mg/ml Linezolid : 2 mg/ml		1925
		Vincristine sulfate : 0.05 mg/ml Melphalan : 0.1 mg/ml		169
		Vincristine sulfate : 0.1 mg/ml Methotrexate sodium : 30 mg/ml		150
		Vincristine sulfate : 0.004 mg/ml Methotrexate sodium : 0.008 mg/ml		431
		Vincristine sulfate : 1 mg/ml Methotrexate sodium : 25 mg/ml		763
		Vincristine sulfate : 1 mg/ml Metoclopramide hydrochloride : 5 mg/ml		763
		Vincristine sulfate : 0.05 mg/ml Ondansetron hydrochloride : 1 mg/ml		334
		Vincristine sulfate : 0,05 mg/ml Oxaliplatin : 0,5 mg/ml		1662
		Vincristine sulfate : 0.05 mg/ml Paclitaxel : 1.2 mg/ml		248
		Vincristine sulfate : 0.05 mg/ml Pemetrexed disodium : 20 mg/ml		1953
		Vincristine sulfate : 0.05 mg/ml Piperacillin sodium / tazobactam : 40/5 mg/ml		81
		Vincristine sulfate : 0.05 mg/ml Sargramostim : 10 µg/ml		335
		Vincristine sulfate : 0.1 mg/ml Sodium bicarbonate : 14 mg/ml		150
		Vincristine sulfate : 0.05 mg/ml Teniposide : 0.1 mg/ml		905
		Vincristine sulfate : 0.05 mg/ml Thiotepa : 1 mg/ml		249
		Vincristine sulfate : 1 mg/ml Topotecan : 0.056 mg/ml		1026
		Vincristine sulfate : 1 mg/ml Vinblastine sulfate : 1 mg/ml		763
		Vincristine sulfate : 0.05 mg/ml Vinorelbine tartrate : 1 mg/ml		84
		Vincristine sulfate : 0.1 mg/ml		150



Bibliographie

	Type	Source
3	Revue	Trissel LA, Martinez JF. Compatibility of amifostine with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1995 ; 52: 2208-2212.
26	Revue	Stewart JT, Warren FW, King DT, Venkateshwaran TG, Ponder GW, Fox JL. Stability of ondansetron hydrochloride, doxorubicin hydrochloride, and dacarbazine or vincristine sulfate in elastomeric portable infusion devices and polyvinyl chloride bags. Am J Health-Syst Pharm 1997 ; 54: 915-920.
32	Revue	Nyhammar EK, Johansson SG, Seiving BE. Stability of doxorubicin and vincristine sulfate in two portable infusion-pump reservoirs. Am J Health-Syst Pharm 1996 ; 53: 1171-1173.
57	Revue	Mayron D, Gennaro AR. Stability and compatibility of granisetron hydrochloride in IV solutions and oral liquids and during simulated Y-site injection with selected drugs. Am J Health-Syst Pharm 1996 ; 53: 294-304.
81	Revue	Trissel LA, Martinez JF. Compatibility of piperacillin sodium plus tazobactam with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1994 ; 51: 672-678.
84	Revue	Trissel LA, Martinez JF. Visual, turbidimetric, and particle-content assessment of compatibility of vinorelbine tartrate with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1994 ; 51: 495-499.
99	Revue	Trissel LA, Martinez JF. Compatibility of aztreonam with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1995 ; 52: 1086-1090.
144	Revue	Dine T, Luyckx M, Cazin JC, Goudaliez F, Mallevais ML. Stability and compatibility studies of vinblastine, vincristine, vindesine and vinorelbine with PVC infusion bags. Int J Pharm 1991 ; 77: 279-285.
150	Revue	Aujoulat P, Coze C, Braguer D, Raybaud C. Physicochemical compatibility of methotrexate with co-administered drugs during cancer chemotherapy regimens. J Pharm Clin 1993 ; 12: 31-35.
167	Revue	Francomb MM, Ford JL, Lee MG. Adsorption of vincristine, vinblastine, doxorubicin and mitoxantrone to in-line intravenous filters. Int J Pharm 1994 ; 103: 87-92.
169	Revue	Trissel LA, Martinez JF. Physical compatibility of melphalan with selected drugs during simulated Y-site administration. Am J Hosp Pharm 1993 ; 50: 2359-2363.
244	Revue	Trissel LA, Martinez JF. Compatibility of filgrastim with selected drugs during simulated Y-site administration. Am J Hosp Pharm 1994 ; 51: 1907-1913.
248	Revue	Trissel LA, Martinez JF. Turbidimetric assessment of the compatibility of taxol with 42 other drugs during simulated Y-site injection. Am J Hosp Pharm 1993 ; 50: 300-304.




249	Revue	Trissel LA, Martinez JF. Compatibility of thiotepa (lyophilized) with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1996 ; 53: 1041-1045.
251	Revue	Trissel LA, Gilbert DL, Martinez JF. Compatibility of doxorubicin hydrochloride liposome injection with selected other drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 2708-2713.
307	Revue	Trissel LA, Martinez JF. Compatibility of allopurinol sodium with selected drugs during simulated Y-site administration. Am J Hosp Pharm 1994 ; 51: 1792-1799.
334	Revue	Trissel LA, Tramonte SM, Grilley BJ. Visual compatibility of ondansetron hydrochloride with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1991 ; 48: 988-992.
335	Revue	Trissel LA, Bready BB, Kwan JW, Santiago NM. Visual compatibility of sargramostim with selected antineoplastic agents, anti-infectives, or other drugs during simulated Y-site injection. Am J Hosp Pharm 1992 ; 49: 402-406.
408	Revue	Beijnen JH, Neef C, Meuwissen OJAT, Rutten JJMH, Rosing H, Underberg WJM. Stability of intravenous admixtures of doxorubicin and vincristine. Am J Hosp Pharm 1986 ; 43: 3022-3027.
431	Revue	McRae MP, King JC. Compatibility of antineoplastic, antibiotic and corticosteroid drugs in intravenous admixtures. Am J Hosp Pharm 1975 ; 33: 1010-1013.
481	Revue	Beijnen JH, Vendrig DEMM, Underberg WJM. Stability of vinca alkaloid anticancer drugs in three commonly used infusion fluids. J Parenter Sci Technol 1989 ; 43: 84-87.
491	Revue	Turowski RC, Durthaler JM. Visual compatibility of idarubicin hydrochloride with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1991 ; 48: 2181-2184.
492	Revue	Trissel LA, Parks NPT, Santiago NM. Visual compatibility of fludarabine phosphate with antineoplastic drugs, anti-infectives, and other selected drugs during simulated Y-site injection. Am J Hosp Pharm 1991 ; 48: 2186-2189.
703	Revue	Butler LD, Munson JM, DeLuca PP. Effect of inline filtration on the potency of low-dose drugs. Am J Hosp Pharm 1980 ; 37: 935-941.
763	Revue	Cohen MH, Johnson-Early A, Hood MA, McKenzie M, Citron ML, Jaffe N, Krasnow SH. Drug precipitation within IV tubing : A potential hazard of chemotherapy administration. Cancer Treat Rep 1985 ; 69: 1325-1326.
857	Revue	Kanke M, Eubanks JL, DeLuca PP. Binding of selected drugs to a "treated" inline filter. Am J Hosp Pharm 1983 ; 40: 1323-1328.
905	Revue	Trissel LA, Martinez JF. Screening teniposide for Y-site physical incompatibilities. Hosp Pharm 1994 ; 29: 1010-1017.
921	Revue	Trissel LA, Gilbert DL, Martinez JF. Incompatibility and compatibility of amphotericin B cholesteryl sulfate complex with selected other drugs during simulated Y-site administration. Hosp Pharm 1998 ; 33: 284-292.
1026	Revue	Mayron D, Gennaro AR. Stability and compatibility of topotecan hydrochloride with selected drugs. Am J Health-Syst Pharm 1999 ; 56: 875-881.

1033	Revue	Wolfe JL, Thoma LA, Du C, Goldspiel BR, Gallelli JF, Grimes GJ, Potti GK. Compatibility and stability of vincristine sulfate, doxorubicin hydrochloride, and etoposide in 0.9% sodium chloride injection. Am J Health-Syst Pharm 1999 ; 56: 985-989.
1408	Revue	Priston MJ, Sewell GJ. Stability of three cytotoxic drugs infusions in the Graseby 9000 ambulatory infusion pump. J Oncol Pharm Practice 1998 ; 4: 143-149.
1410	Revue	Trissel LA, Martinez JF, Simmons M. Compatibility of etoposide phosphate with selected drugs during simulated Y-site injection. J Am Pharm Assoc 1999 ; 39: 141-145.
1423	Revue	Trissel LA, Martinez JF, Gilbert DL. Compatibility of gemcitabine hydrochloride with 107 selected drugs during simulated Y-site injection. J Am Pharm Assoc 1999 ; 39: 514-518.
1496	Revue	Trissel LA, Martinez JF, Gilbert DL. Screening cladribine for Y-site physical compatibility with selected drugs. Hosp Pharm 1996 ; 31: 1425-1428.
1520	Laboratoire	Etude de stabilité des médicaments en Ecoflac® B Braun 2001
1602	Revue	Trissel LA, Zhang Y, Cohen MR. The stability of diluted vincristine sulfate used as a deterrent to inadvertent intrathecal injection. Hosp Pharm 2001 ; 36: 740-745.
1606	Revue	Yuan P, Grimes GJ, Shankman SE, Daniels CE, Goldspiel BR, Potti GK. Compatibility and stability of vincristine sulfate, doxorubicin hydrochloride, and etoposide phosphate in 0.9% sodium chloride injection. Am J Health-Syst Pharm 2001 ; 58: 594-598.
1625	Revue	Trissel LA, Saenz C, Williams YW, Ingram D. Incompatibilities of lansoprazole injection with other drugs during simulated Y-site coadministration. Int J Pharm Compound 2001 ; 5: 314-321.
1662	Revue	Trissel LA, Saenz CA, Ingram DS, Ogundele AB. Compatibility screening of oxaliplatin during simulated Y-site administration with other drugs. J Oncol Pharm Practice 2002 ; 8: 33-37.
1925	Revue	Trissel LA, Williams KY, Gilbert DL. Compatibility screening of linezolid injection during simulated Y-site administration with other drugs and infusion solutions. J Am Pharm Assoc 2000 ; 40: 515-519.
1953	Revue	Trissel LA, Saenz CA, Ogundele AB, Ingram DS. Physical compatibility of pemetrexed disodium with other drugs during simulated Y-site administration. Am J Health-Syst Pharm 2004 ; 61: 2289-2293.
1982	Revue	Trissel LA, Ogundele AB. Compatibility of anidulafungin with other drugs during simulated Y-site administration. Am J Health-Syst Pharm 2005 ; 62: 834-837.
2094	Revue	Trittler R. Stability of intravenous admixtures of doxorubicin and vincristine confirmed by LC-MS. EJHP Science 2006 ; 12, 1: 10-12.
2247	Revue	Chan P, Heatherly K, Kupiec T.C, Trissel L.A. Compatibility of caspofungin acetate injection with other drugs during simulated Y-site coadministration. Int J Pharm Compound 2008 ; 12, 3: 276-278.
3119	Poster	Henriet Th, El Kateb N, Jourdan N, Faure P, Bellenger P. Stabilité de la vincristine sans conservateurs. Congrès HOIPHARM 2010

3214	Revue	Trittler R, Sewell G. Stability of vincristine (TEVA) in original vials after re-use in dilute infusions in polyolefin bags and in polypropylene syringes. EJOP 2011 ; 5,1: 10-14.
3578	Laboratoire	Cisplatin - Summary of Product Characteristics Accord Healthcare 2011
3644	Laboratoire	Calcium gluconate® - Summary of Product Characteristics Hameln Pharmaceuticals 2010
4102	Revue	Svirskis D, Behera S, Naidoo N, Beachman J, Raina T, Zhou Y, Berkahn L, Costello I, Gu Y. Stability of vincristine sulfate, doxorubicin hydrochloride and etoposide phosphate admixtures in polyisoprene elastomeric pump supporting transition of the EPOCH regimen to outpatient care. J Oncol Pharm Practice 2018 ;25,4:831-840.



Dictionnaire

 Anticancéreux	 Injectable
 Noms commerciaux	 Stabilité des solutions
 Contenant	 Molécule
 Concentration	 Température
 Conservation	 Durée de stabilité
 Biosimilaire	 Données conflictuelles
 Bibliographie	 Verre
 Eau pour préparation injectable	 A l'abri de la lumière
 Jour	 Polyvinyl chlorure
 NaCl 0,9% ou glucose 5%	 Chlorure de sodium 0,9%
 Polyéthylène	 Polypropylène
RL Ringer lactate	 Polyoléfine
 Seringue polypropylène	 Stabilité en mélange
 Solvant	 Molécule
 Lumière	 Heure
 Non précisée	 Avec ou sans lumière
 Polysiloxanne	 NaCl 0,45% Glucose 2,5%
 Elastomère en polyisoprène	 Non précisé
 Facteur influençant la stabilité	 Filtration
 Provoque	 Adsorption
 NaHCO ₃	 Dégradation
 Compatibilités	 Compatible
 Glucose 5%	 Incompatibilité non précisée
 Incompatible	 Instabilité chimique
 NaCl 0,9% + bactériostatique	 Précipitation immédiate
 Changement de couleur	 Aucun
 Précipitation en 30 minutes	 Voie d'administration
 Perfusion intraveineuse	 Perfusion continue
 Bibliographie	 Dictionnaire